Original contributionDuctal carcinoma in situ of the breast: Reproducibility of histological subtype analysis☆
References (21)
- et al.
Duct carcinoma in situ 227 cases without microinvasion
Eur J Cancer
(1992) - et al.
Noninvasive ductal carcinoma of the breast: The relevance of histologic categorization
Hum Pathol
(1993) - et al.
Ductal carcinoma in situ of the breast with apocrine cytology: Definition of a borderline category
Hum Pathol
(1994) Duct carcinoma in situ: Pathology and treatment
Surg Clin North Am
(1990)- et al.
Long-term follow-up in situ carcinoma of the breast
Sermin Diagn Pathol
(1994) One century of mammary carcinoma in situ: What have we learned?
Am J Clin Pathol
(1993)- et al.
Intraductal carcinoma of the breast: Follow-up after biopsy only
Cancer
(1982) - et al.
Noninfiltrating (In Situ) Carcinoma
- et al.
Carcinoma in situ and patients at high risk of breast cancer
BMJ
(1995) - et al.
Continued local recurrence of carcinoma 15–25 years after biopsy only for low grade ductal carcinoma in situ of the breast
Cancer
(1995)
Cited by (95)
Breast intraductal nanoformulations for treating ductal carcinoma in situ I: Exploring metal-ion complexation to slow ciclopirox release, enhance mammary persistence and efficacy
2020, Journal of Controlled ReleaseCitation Excerpt :DCIS lesions are classified as low, intermediate, or high grade based mostly on their nuclear grade and expression of Ki-67 [3]. The alteration in genetic expression for low-grade DCIS highly resembles that of atypical ductal hyperplasia, while the expression of the oncogenic pathway and molecular markers for high-grade DCIS are the same as invasive ductal carcinoma (IDC) [4,5]. The probability of progressing to invasive cancer after ten years in untreated patients is notably lower in low grade (16%) as compared to high grade DCIS (60%) [6,7].
In situ carcinomas of the breast: Ductal carcinoma in situ and lobular carcinoma in situ
2018, The Breast: Comprehensive Management of Benign and Malignant DiseasesThe diagnostic challenge of low-grade ductal carcinoma in situ
2017, European Journal of CancerFinding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS)
2017, BreastCitation Excerpt :Reliability studies are hard to compare as they often differ in study design. Also they are limited due to: mostly examining a small number of highly selected cases [35,40–45]; being assessed by expert breast pathologists only and; often after being giving instructions or tutorials beforehand [35,41,42,45,46]. Translation of these findings into daily practice is therefore questionable and, so far, has not reduced inter-observer variability.
Current Approaches to Diagnosis and Treatment of Ductal Carcinoma In Situ and Future Directions
2017, Progress in Molecular Biology and Translational ScienceImaging Features of Micropapillary DCIS: Correlation with Clinical and Histopathological Findings.
2011, Academic RadiologyCitation Excerpt :The traditional classification of DCIS is into comedo and noncomedo (cribriform, micropapillary, and solid) subtypes. The micropapillary subtype of DCIS is associated with more extensive disease at diagnosis, irrespective of nuclear grade or presence of necrosis (3,4,12). To date, there are limited data on the imaging characteristics of the micropapillary subtype of DCIS.
- ☆
Presented in part at the United States and Canadian Academy of Pathologists Meeting, Toronto, Canada, March 1995.